Similar to the xenograft model, NOX4 inhibition (shRNA) (Supplementary Figure 5, B–E, available online) and GKT137831 (Supplementary Figure 5, F–H, available online) statistically significantly reduced myofibroblast accumulation (79.0%, 95% CI = 66.0% to 92.0%, and 76.3%, 95% CI = 54.1% to 98.6%, respectively, P < .001) and tumor growth (64.0%, 95% CI = 30.9% to 97.1%, and 30.6%, 95% CI = 1.9% to 59.3%, respectively, P ≤ .04). Here, NOX4 is linked to neoplasm.